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Endogenous neuropeptides, acting as neurotransmitters or hormones in the brain, carry out
important functions including neural plasticity, metabolism and angiogenesis. Previous
neuropeptide studies have focused on peptide-rich brain regions such as the striatum or
hypothalamus. Here we present an investigation of peptides in the visual system, com-
posed of brain regions that are generally less rich in peptides, with the aim of providing
the first broad overview of peptides involved in mammalian visual functions. We target
three important parts of the visual system: the primary visual cortex (V1), lateral geniculate
nucleus (LGN) and superior colliculus (SC). Our study is performed in the tree shrew, a
close relative of primates. Using a combination of data dependent acquisition and tar-
geted LC-MS/MS based neuropeptidomics; we identified a total of 52 peptides from the
tree shrew visual system. A total of 26 peptides, for example GAV and neuropeptide K
were identified in the visual system for the first time. Out of the total 52 peptides, 27
peptides with high signal-to-noise-ratio (>10) in extracted ion chromatograms (EIC) were
subjected to label-free quantitation. We observed generally lower abundance of peptides
in the LGN compared to V1 and SC. Consistently, a number of individual peptides showed
high abundance in V1 (such as neuropeptide Y or somatostatin 28) and in SC (such as
somatostatin 28 AA1-12). This study provides the first in-depth characterization of
peptides in the mammalian visual system. These findings now permit the investigation
of neuropeptide-regulated mechanisms of visual perception.
1. Introduction
Neuropeptides are evolutionarily old neurotransmitters pre-
sent in all species possessing a nervous system [1]. They are
involved in regulating many physiological pathways [2–6].
Their functions and expression levels can differ considerably
across particular brain areas [7]. In the visual system, peptides
were found to carry out important functions related to develop-
ment [8], neural plasticity, regulation of blood flow and energy
metabolism [7,9]. Neuropeptides also play a key role in the
development and function of the inhibitory circuits that shape
the visual system in response to experience [10] and their ex-
pression patterns are different in relation to morphologically
and physiologically distinct interneuron classes [11].
⁎ Corresponding author at: Visual Cognition Laboratory, Department of Medicine, University of Fribourg, Chemin de Musee 5, Fribourg, CH-1700,
Switzerland. Tel.: +41 263008910; fax: +41 263009734.
E-mail address: xiaozhe.zhang@unifr.ch (X. Zhang).


Published in -RXUQDORI3URWHRPLFV±
which should be cited to refer to this work.
ht
tp
://
do
c.
re
ro
.c
h
To advance our understanding of peptide functions in the
visual system, we sought to provide an in-depth simultaneous
characterization of a large set of peptides present in different
substructures of the visual system. Compared to peptides pre-
viously identified in peptide-rich areas such as hypothalamus
[12] or striatum [13], peptides in the visual system have so far
received relatively little attention using mass spectrometry
approaches.
Neuropeptides, from an analytical chemistry point of view,
have been characterized predominantly by employing im-
munoassay or radioimmunoassay [14,15]. Classical immuno-
chemical approaches are usually used to characterize only a
few peptides or peptide families within a single study, but it
is usually difficult to distinguish between similar peptides
from one peptide family. Contrastingly to mass spectromet-
ric approaches, immunohistochemical or radiography also
cannot provide a complete image of peptides in the studied
brain region. Mass spectrometric approaches offer several
advantages including higher sensitivity and throughput com-
pared to traditional methods [16–21]. For example, recent neu-
ropeptidomics studies have demonstrated high sensitivity
characterization of peptides in diverse tissues such as human
brain [22–25], and rat brain [26–30]. Moreover, several protocols
for peptide characterization usingmass spectrometry as ana-
lytical tools have been developed and are used routinely for
biomedical applications [16,17,31,32].
Here, we thus sought to characterize the peptide popula-
tion and its distribution across three important parts of the
visual system using tree shrews (Tupaia belangeri) as model
animals. Tree shrews are phylogenetically close relatives of
primates, and similar to primates, they have a well-developed
visual system and therefore are frequently used as animal
models for the study of visual structure and function [33].
The three relevant visual centers targeted for neuropeptide
characterization in this study are the primary visual cortex
(V1), lateral geniculate nucleus (LGN) and superior colliculus
(SC); the regions are schematically shown in the Fig. 1A. We
have identified 52 peptides from 21 precursor families in the
tree shrew visual system in the three targeted brain regions.
This peptide population includes 21 classical neuropeptides
that have been previously identified, as well as 26 peptides
previously not reported in visual system. We have also used
a label free quantification approach to evaluate the relative
abundances of a subset of 27 peptides in the studied brain
regions. We discuss our findings in relation the possible
peptide functions in the visual system in light of previous
literature.
2. Methods
2.1. Chemicals
LC-MS grade acetonitrile and formic acid were purchased from
Fisher Scientific (New Jersey, USA) and Fluka (Wisconsin, USA),
respectively. Pure water was prepared by GenPure system (TKA,
Niederelbert, Germany) Siliconized micro centrifuge tubes
(2 mL) were purchased from Eppendorf (Hamburg, Germany).
Microcon centrifugal filter devices (Vivacon 500) were purchased
from Sartorius AG (Goettingen, Germany Germany).
2.2. Animals
Tree shrews (Tupaia belangeri) were used as model animals.
They were housed at constant temperature and humidity
with free access to food and water. All procedures were in
compliance with applicable European Union (EUVD 86/609/
EEC) and Swiss regulations. Three male tree shrews, six
years old, were sacrificed by a decapitation after having been
anaesthetized with ketamine (Streuli Pharma AG, Uznach,
Switzerland).
2.3. Sample preparation
During sample preparation, temperature control was used to
minimize the degeneration of the endogenous neuropeptides
and also to reduce the interference of peptides produced by
degradation of proteins. Tree shrew heads were immediately
heated up to 80 °C for 16 s using microwave irradiation [34].
Their brains were removed and stored at −80 °C, and visual
system parts were dissected from the denatured brain, right
and left half brains separately. For each extraction, 10.0 mg
of brain tissue was used. Neuropeptides were extracted from
6 samples from both brain hemispheres (V1, LGN and SC).
We used a four step extraction procedure that had been de-
veloped previously[35]. Briefly, it is based on a distinct gradi-
ent of organic phase (methanol) solutions, which were used
as follows: firstly an aqueous solution of 0.2% acetic acid
was used two times, then a methanol–water-actic acid solu-
tion (20:79.8:0.2, v/v/v) was selected and finally the last ex-
traction part was performed using a methanol–water-acetic
acid solution (50:49.8:0:2, v/v/v). Each of the four steps used
15 micro liters of solvent per one mg of brain sample. Before
an extraction, samples had been homogenized twice (each
time for 20 s) within 1 min by a Precellys 24 homogenizer
(Bertin Technologies, Montigny-le-Bretonneux, France). After
homogenization, they were centrifuged at 22, 000 g for
60 min at 4 °C. Before analysis, obtained supernatants from
the first two steps (aqueous phase) as well as the superna-
tants from the last two steps (organic phase) had been
mixed together and filtered using a 10 kDa cut-off filter
(Vivacon 500, Sartorius AG, Goettingen, Germany) by centrifug-
ing for 90 min with 14.000 g at 4 °C. Finally, aqueous and
organic peptide extracts were pooled together on a trap col-
umn (100 μm ID, 2 cm long), which had been previously
packed with a C18 AQ particles (5 μm, 100 Å;) and afterwards
they were injected on an analytical column based on C18 AQ
(3 μm, 100 Å) stationery phase which was packed in a Pico-
frit capillary with an emitter tip of 10 μm (NewObjective)
and analyzed.
2.4. LC-FT-MS/MS data acquisition
For all mass spectrometric experiments, LTQ-Orbitrap Dis-
covery (Thermo Fisher Scientific, Bremen, Germany) hyphen-
ated with a 2D NanoLC (Eksigent Technologies, USA) was
used. Firstly, samples were injected 5 times on a trap column
in a peek column holder (Upchurch). Each injection was 5 μl
and the interval between injections was 3 min. Trapped
analytes were eluted using 2% acetonitrile and 98% water
containing 0.2% formic acid. The mobile phase A and B in
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2D pump were 0.2% formic acid, and 95% acetonitrile con-
taining 0.2% formic acid, respectively. The flow rate was set
to 300 nl/min with the following gradient profile: 0–6 min,
2% B; 6–12 min, 2–20% B; 12–80 min, 20–50% B; 80–85 min,
50–60% B; 85–90 min, 60–95% B; and 90–100 min, 95% B.
After each LC-MS run, the LC system was cleaned by an in-
jection of 75% acetonitrile containing 0.1% formic acid two
times and then conditioned for a next analysis. The mass
spectrometric parameters of an LTQ-FTMS instrument con-
sisted of a full FTMS scan event at a mass range from 350
to 2000m/z and data-dependent analysis (DDA) CID MS/MS
scans (30,000 resolutions) of the five most abundant peaks
from the previous full FTMS scan. All key experimental pa-
rameters concerning the mass spectrometric methods were
tuned to obtain suitable spectra of selected internal stan-
dards (NPY, Neurotensin; concentration level 5×10−6 mol.L−1);
i.e.: spray voltage, nanospray geometry, heated capillary
temperature and ion optics parameters were tuned. Mini-
mum signal threshold of a data dependent scan for the 1st
and 5th most intensive ions were set at 5000, 3000, 1000,
1000 and 1000 counts, respectively. Other MS/MS parame-
ters were set as follows: isolation width, m/z=2; normalized
collision energy, 25%; activation Q, 0.25; and activation
time, 50 ms. Dynamic exclusion was set as a repeat count
of 1, an exclusion duration of 180 s, and a repeat duration
of 30 s.
Firstly, all the obtained DDA LC-FTMS/MS data were sub-
jected to Peaks Studio 5.3 (BSI, Canada) hybrid spectral anal-
ysis using homemade database of potential neuropeptide
precursors of T. belangeri obtained from Euarchontoglires
datasets and BLAST homology search using UNIPROT/SWIS-
SPROT databases with false discovery rate control (peptide
sequence FDR <1%). Secondly, we used a targeted LC-MS/
MS analysis, with an inclusion list integrated from two
independent sources: i) the list of peptides identified in
the first step using the DDA approach ii) the previous find-
ings by Petruziziello et al. [36] performed on tree shrew
striatum (peptide sequence FDR <1%). The final workflow
is shown in the Fig. 1B. Identification of peptides was based on
several inclusion criteria: a) the monoisotopic mass of target
had to match the theoretical mass in the database with an
error no higher than 5 ppm. b) the fragmentation spectrum of
each target peptide has to be well interpreted and fragment
ions has to be measured with an error lower than 0.05 Da. c)
The isotopic pattern of identified peptides has to match the
theoretical model and finally d) each peptide has to have a
clearly defined peak in the respective reconstructed ion
chromatogram with S/N ratio higher than 3. Finally, each
identified peptide was manually checked in the correspond-
ing raw file and only high confidence peptides are reported.
Peptide information obtained by a combination of these two
approaches is included in the Table 1. The peptides with S/N
Fig. 1 – A: The scheme of brain sections analyzed in this study. Namely LGN, SC and V1 were investigated. B.: The workflow
used in this particular study. Samples were subjected to extraction; extracts were analyzed firstly using DDA mode and
afterwards confirmed using Target-mass list mode. Identified entities were subjected to label free quantification.
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Table 1 – The list of identified peptides present in the visual system of Tupaia belangeri. Identification was performed using the combination of DDA and targeted LC-MS/MS
analysis.
Peptide label Family Name Sequence −10lgP ppm m/z Charge state Protein accession
15 ACA polypeptide 1 EILNEAYRKVLDQL(−0.98) 44.23 7.7 568.33 3 sp|P13589|PACA_RAT
1 Acyl-CoA-binding protein VEKVEELKKKY 41.31 2 464.94 3 15_sp|P11030|ACBP_RAT
17 CARTa Q(−17.03)EDAELQPR.A 44.85 2.6 534.75 2 sp|P49192|CART_RAT
2 Cholecystokinin Q(−17.03)SLDPSHRIS 52.47 1.3 561.78 2 18_sp|P09240|CCKN_MOUSE
16 Chromogranin B QYDGVAELDQLLHY 44.85 2.1 832.40 2 sp|P16014|SCG1_MOUSE
3 Delta pre-protachykinin Ia DAGHGQISHKMGYE 56.46 0.2 510.57 3 12_tr|Q9Z0K2|Q9Z0K2_CAVPO
6 Gamma preprotachykinin LPEPFEHLLQ 41.33 2.5 611.83 2 sp|P20366|TKN1_HUMAN
4 Neuroendocrine protein 7B2a SVNPYLQGQRLDNVVA 48.15 2.6 886.97 2 27_tr|Q2PFP9|Q2PFP9_MACFA
20 Neuropeptide FF receptor 1 AMFIAAYALIFLLCMVGNT 37.78 6.5 516.03 4 sp|P05408|7B2_HUMAN
42 Neuropeptide Ya Neuropeptide Y YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY(−.98) 65.33 1.2 854.83 5 sp|P07808|NPY_RAT
22 Neurosecretory-protein VGF AQEE-30 AQEEAEAEERRLQEQEELENYIEHVLLRRP 44.85 0.2 742.17 5 sp|O15240|VGF_HUMAN
21 Neurosecretory-protein VGFa Neuroendocrine regulatory peptide-2 EQEELENYIEHVLLRRP 44.85 0.0 723.04 3 sp|O15240|VGF_HUMAN
9 Neurotensin Neurotensin Q(−17.03)LYENKPRRPYIL 43.27 −0.1 558.31 3 8_sp|Q9D3P9|NEUT_MOUSE
23 Nucleobindin-2 FLEPDSWETLDQQQLF 49.79 3.2 499.49 4 sp|Q9JI85|NUCB2_RAT
11 Prodynorphina Dynorphin B YGGFLRRQFKVVT 12.5 −1.5 393.48 4 sp|O35417|PDYN_MOUSE
5 ProEnkephalin A GRPEWWMDYQ 51.56 2.1 684.30 2 40_sp|P47969|PENK_CAVPO
7 ProEnkephalin Aa VGRPEWWMDY 56.16 0.7 669.80 2 40_sp|P47969|PENK_CAVPO
18 ProEnkephalin Aa Metankephaline YGGFM 28.14 −0.3 574.23 1 40_sp|P47969|PENK_CAVPO
8 ProEnkephalin Aa YGGFMRF 51.39 1.1 439.21 2 37_sp|P01210|PENK_HUMAN
33 Proenkephalin-A LPSDEEGESYSKEVPEM 44.85 0.4 963.42 2 sp|P04094|PENK_RAT
34 Proenkephalin-A ALPSDEEGESYSKEVPEM 44.85 1.7 998.94 2 sp|P04094|PENK_RAT
35 Proenkephalin-A LPSDEEGESYSKEVPEME 44.85 1.1 1027.94 2 sp|P04094|PENK_RAT
36 Proenkephalin-A ALPSDEEGESYSKEVPEME 44.85 1.8 1063.46 2 sp|P04094|PENK_RAT
19 Proenkephalin-A GRPEWWMDYQ 44.85 6.4 684.30 2 sp|P04094|PENK_RAT
26 ProEnkephalin-Aa Leu-enkephalin YGGFL 22.68 −1.4 556.28 1 40_sp|P47969|PENK_CAVPO
27 ProEnkephalin-Aa Met-enkephalin-Arg-Gly-Leu YGGFMRGL 59.4 −0.3 450.72 2 40_sp|P47969|PENK_CAVPO
28 Pro-melanin-concentrating hormone EIGDEENSAKFPI(−.98) 44.85 4.5 724.36 2 sp|P14200|MCH_RAT
25 Pro-melanin-concentrating hormonea DFDMLRCMLGRVYRP 44.85 1.5 624.64 3 sp|P14200|MCH_RAT
29 Pro-melanin-concentrating hormonea Neuropeptide-glutamic acid-isoleucine EIGDEENSAKFP 44.85 4.5 724.36 2 sp|P14200|MCH_RAT
30 Pro-SAAS PPEGVLGALLR 44.85 3.1 561.34 2 sp|Q9UHG2|PCSK1_HUMAN
31 Pro-SAAS PPEGVLGALLRV 44.85 4.0 610.87 2 sp|Q9UHG2|PCSK1_HUMAN
32 Pro-SAAS PRGEAAGAVQELARALAHLLEAERQE 44.85 3.8 697.13 4 sp|Q9UHG2|PCSK1_HUMAN
38 Pro-SAASa GAV AVPRGEAAGAVQELARALAHLLEAERQE 45.1 1 739.65 4 sp|Q9UHG2|PCSK1_HUMAN
41 Pro-tachykinin-1a Neuropeptide K (frag) DADSSIEKQVALLKALYGHGQISH 45.2 1.2 645.84 4 sp|Q9UHG2|PCSK1_HUMAN
43 Secretogranin 1a Q(−17.03)YDGVAELDQLLHY 59.2 −0.7 823.89 2 72_sp|P16014|SCG1_MOUSE
37 Secretogranin-1 QLDLKRQY(−.98) 37.93 6.9 531.81 2 sp|P16014|SCG1_MOUSE
24 Somatostatin K.AGCKNFFWKT 44.85 2.7 401.20 3 sp|P60042|SMS_RAT
44 Somatostatin APSDPRLRQFLQ 45.21 7.1 476.60 3 sp|P60042|SMS_RAT
10 Somatostatina Somatostatin 14 AGCKNFFWKTFTSC 55.4 −0.5 820.37 2 3_tr|Q7TSR3|Q7TSR3_9MURI
39 Somatostatina Somatostatin – 28 SANSNPAMAPRERKAGCKNFFWKTFTSC 44.85 3.2 788.13 4 sp|P60042|SMS_RAT
40 Somatostatina Somatostatin – 28 (1–12) SANSNPAMAPRER 44.85 3.1 622.79 2 sp|P60042|SMS_RAT
12 Somatostatina FFWKTFTSC 41.51 −1.2 583.77 2 3_tr|Q7TSR3|Q7TSR3_9MURI
13 Substance P Substance P RPKPQQFFGLM(−.98) 42.09 −3.3 674.37 2 10_sp|Q60541-2|TKN1_MESAU
45 Tachykinin 1a Substance P fragment PKPQQFFGLM(−.98) 44.85 1.4 596.32 2 sp|P06767|TKN1_RAT
14 VIP peptidesa [pGlu16] – VIP (16–28), porcine Q(−17.03)MAVKKYLNSILN(−.98) 47.24 2 752.42 2 4_sp|P32649|VIP_RABIT
(*) Peptide with a substitution of one or two amino acids, identified using homology search.
(−17.03): Glutamination.
(−.98): Amidation.
ppm: Error in ppm.
a Classical peptide previously identified in other brain part or other specie.
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ratio higher than 10 and CV below 50% were also relatively
quantified.
2.5. Label free quantification
For a label free quantification of identified peptides the SIEVE
(Version 1.3, Thermo Scientific, U.S.A.) and Matlab 2009b
(Mathworks, Natick, Massachusetts, U.S.A.) were used. The
label free quantification is based on the direct comparison of
peak areas in respective extracted ion chromatograms of
previously identified peptides [37]. The data processing in-
cludes mainly three steps: i) precursor ion extraction with
narrow mass window; ii) peak alignment; and iii) peak area
integration. After obtaining the peak areas, further normali-
zation is used for differential analysis (see method below).
The Sieve software is a powerful tool for label free quantifi-
cation and is used for comparison of various compounds
levels across diverse samples. In this study, it served as a
data alignment tool with following parameters: m/z range
from 300 to 1500 Da, time frame 6 min, m/z frame 0.02 Da
with a peak intensity threshold 10,000.
2.6. Data normalization
The process of data normalization presents an important
step in the data evaluation. The selection of normalization
procedure could dramatically influence the obtained results
and thus a careful evaluation of normalization approach
has to be accomplished [38]. The normalization across all
respective datasets was performed as follows: total abun-
dance of each peptide across all three respective brain areas
was calculated (set as 100%) and the mean expression level
was used as a reference point for a calculation of the relative
abundance of each peptide in particular brain parts. The label
free quantification of respective identified peptides was ex-
ecuted on previously normalized data. All normalizations
and calculations were performed using Matlab scripts. Firstly,
the t-tests were used to compare peptide signal intensities in
the left and right half brains and among samples from the
same group. We found no statistically significant differences
in peptide signal intensities between left and right hemispheres
(paired t-tests, P>0.05).
3. Results
3.1. Wide-ranging identification of neuropeptides in V1,
CSR and LGN
The first aim of the present study is a broad discovery of
peptides present in primary visual cortex and two subcorti-
cal visual areas, the LGN and SC. In this study, we used an
integration of DDA and targeted LC-MS/MS analysis to in-
crease the peptide identification rates. This mode has been
previously applied in a proteomics to increase the capability
of identification of low abundant peptides. A database search
allowed the identification of 52 peptides from 21 pro-hormone
families with high confidence. The peptides with their identi-
fication details are summarized in Tables 1 and 2. In addition,
we found 6 classical neuropeptides that were known to be
present in other brain structures but had not been previously
reported in the visual system. Classical peptides are labeled
with a “#” symbol in Table 1. Finally, we have identified 7
peptides in the visual system, which exhibit substitutions
of one or two amino acid residues in comparison with known
peptides in other species. They are labeled with “*” symbol in
Table 2. Among our identified peptides, we found 7 peptides
with amidation and 5 peptides with glutamination post-
translational modifications (PTMs) (for details see Table 1).
PTMs play an important role in the activation of native neuro-
peptides and also canact asprotectors against unwanteddegra-
dation processes.
3.2. Comparative analysis of peptides expressed in differ-
ent visual areas
The second aim of our study was a comparative analysis of
the three selected visual areas, based on an evaluation of nor-
Table 2 – The list of peptides identified in the visual system of Tupaia belangeri using homology search.
Peptide label Peptide sequence Homology
search
SPIDER
score
RSD ppm m/z Charge
state
Protein accession
46 SPFDNKLNVEDVDST a 43 0.07 2.3 840.4 2 49_sp|Q8WXD2|
SCG3_HUMAN
47 SPQLDDEAKELQ a 31.5 0.17 1.7 686.8 2 20_sp|P47969|PENK_CAVPO
48 SPQLDDEAKEL a 28 0.18 −0.1 622.8 2 1_sp|P47969|PENK_CAVPO
49 SPQLDDEAKE a 25.5 0.2 −0.8 566.3 2 1_sp|P47969|PENK_CAVPO
50 FLGEGYHQVQES a 24 0.25 1.1 697.3 2 8_tr|B2R5M3|
B2R5M3_HUMAN
51 FLGEGYHQVQE a 21 0.27 0.7 653.8 2 8_tr|B2R5M3|
B2R5M3_HUMAN
52 K.LDELQKQWKEDLER.Qa a 20.77 0.29 7 610.7 3 sp|Q9JI85|NUCB2_RAT
(−17.03): Glutamination.
(−.98): Amidation.
RSD: Relative standard deviance.
ppm: Error in ppm.
a Peptide with a substitution of one or two amino acids, identified using homology search.

ht
tp
://
do
c.
re
ro
.c
h
malized peak areas processed according to the protocol de-
scribed in the Methods section. Fig. 2 summarizes this data
by showing label, name and relative abundance for all the
peptides in our population, which were subjected to
relative quantification (S/N>10, CV<50%). The data are
normalized such that the total abundance of each peptide
in the three brain regions is expressed as 100%. It is evident
that the peptides subjected to quantification are present,
albeit at differing concentrations, in all of the targeted
brain regions. To examine differences in peptide distribu-
tion between areas, we plotted relative peptide abundance
across each pair of visual areas: V1 and SC, V1 and LGN
and finally, LGN and SC (see Fig. 3). Each dot represents a
mean relative expression level (related to a total peak
area across studied brain parts and ranging from 0 to
100%) of the selected peptide, while its label corresponds
to the peptide ID in Table 1. We found that both V1 and
SC regions were more rich in peptides compared to the
LGN (paired t-tests, P<0.05), while there was no general
difference in peptide abundance between V1 and SC (paired
t-test, P>0.1).
To examine the distribution of targeted peptides, we plot-
ted box-plots for each studied brain region, showing the
statistical evaluation of each peptide in the distribution;
each box is based on six independent measurements. It is
clear that some of the peptides have more specific distribu-
tion and are localized mainly in primary visual cortex or
one of the subcortical regions. For example Somatostatin
28 (peptide label 39) is more abundant in V1, whereas the rest
of this peptide family, including Somatostatin 28 AA1-12
(peptide label 40) and Somatostatin fragment (peptide label
12) are more abundant in subcortical areas, consistent
with previous findings using immunoassays [39]. Similarly,
Cholecystokinin (peptide label 2) is also observed with
higher abundance in V1. On the contrary, we also observed
peptides with high abundances in the subcortical areas LGN
and SC. An example is the CART peptide (peptide label 17) or
Neuroendocrine protein 7B2 (peptide label 4), which are more
abundant in SC and LGN, compared to V1. It is worth mention-
ing that NPY (peptide label 42) is distributed in all studied
brain regions and exhibits a higher abundance in V1 compared
to SC and V1 (Fig. 4).
Fig. 2 – Reconstructed histogram with relative expression levels of quantified peptides across target visual centers.
Fig. 3 – Scatter plots of ratios of normalized areas of peptides
across each two brain regions. Point labels represent peptide
ID found in the Table 1. Primary visual cortex, Superior
colliculus and Lateral geniculate nucleus were taken into
account. Analysis consists of 27 relatively quantified
peptides.

ht
tp
://
do
c.
re
ro
.c
h
4. Discussion
Our study targets the comprehensive characterizationof peptide
population in the visual system of the tree shrew (T. belangeri).
The study of the peptide population in visual system is
challenging, mainly due to the low abundance of many
peptides compared to peptide-rich brain areas such as the
striatum [40]. To provide as complete as possible view of the
peptide population in the visual system, we utilized MS-based
neuropeptidomics. Our methodological approach utilizes on
the integration of data dependent acquisition (DDA) and
target-mass list modes, with a mass list based on the previ-
ous DDA runs and also on the analysis of peptide rich areas
of T. belangeri, i.e. striatum, performed previously [36]. Using
this integrated approach, we achieved an identification of
52 peptides from 21 pro-hormone families, including 11 pro-
enkephaline (PENK), 6 Somatostatin (SOM) and three Pro-
MCH peptides. A total of 26 peptides, for example GAV, NPK
or AQEE-30, were identified in the visual system for the first
time. Our differential analysis uncovered that peptides are
generally present at lower abundance in the LGN compared
to V1 and SC. To our knowledge, this is the first such demon-
stration in the mammalian visual system, although similar
findings have been reported in frogs [41,42]. The low abun-
dance of peptides in the LGN might be related to the func-
tional role of this brain area as a relay station of signals from
the eye to the brain, where little signal processing occurs in
comparison with for example the visual cortex.
We have identified several peptides from the Tachykinin
I family [43], including Substance P, Substance P fragment
and Neuropeptide K. For example, previous immune-assay
studies showed that substance P is present in SOM positive
neurons of the visual cortex during development, while its
expression is down-regulated to be absent in adulthood
[44]. Our experiment clearly revealed that substance P per-
sists in visual cortex as well as SC and LGN in adult ani-
mals, reflecting the superior sensitivity and selectivity of
MS-based neuropeptidomics.
We also identified six peptides from the somatostatin
family (SOM), including SOM 28, SOM 28 AA1-12 and SOM 14.
Somatostatins are expressed by about one third of GABAergic
interneurons, and about 90% of SOM neurons are GABAergic
[45]. We observed a high abundance of SOM 28 in the primary
visual cortex, consistent with previous findings obtained
using radiography evaluation of binding sites in the human
brain [46,47], as well as in cat and monkey [48]. In contrast,
we found that SOM 28 AA1-12 was present at high abundance
in the superior colliculus. This is also consistent with previ-
ous findings based on autoradiography measurements in
mouse [49], dog [50] and sheep [51] colliculus. This shows that
different members of the Somatostatin family are expressed
preferentially in different parts of the visual system. Using
our MS approach, we are able to simultaneously distinguish
six somatostatins, which enhances possibilities for assigning
specific physiological functions to particular members of this
peptide family.
Neuropeptide Y (NPY) is one of the key classical neuropep-
tides, playing a key role in the functions of the visual system
[52]. NPY levels in visual cortex undergo specific changes
during visual system development that are dependent on
visual input, and it is thus thought to be important for the
processing of visual information [53]. We found that NPY is
distributed non-homogenously in the three studied visual
system areas, with high abundance observed in V1. Our
finding correlates with previous immunochemical results
Fig. 4 – Reconstructed bar plots of quantified peptide population. Each brain regions is expressed individually for in-depth
comparison. Plus signs stand for outliers; extreme points are represented by the whiskers.
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in lizard [54] and cat [55], showing a high density of NPY
fibers in cortical areas, contrasting low fiber density in other
regions such as the thalamus.
Our study also relatively quantified peptides from the Pro-
Enkephaline family, where higher abundances were found in
primary visual cortex, compared to SC and LGN. Enkepha-
lines have been previously observed using histochemistry
in the visual cortex of cat and turtle [56,57], where a layer-
dependence has also been described with the highest En-
kephalin abundance occurring in layer VI. Although we did
not do so here, MS methods can in principle also be used to
study peptide distribution across cortical layers. Also consis-
tent with our results are previous reports of Enkephalines in
the superior colliculus [58]. While Enkephalins have been
mostly associated with addiction and pain, our studies sug-
gest that they may also play an important role in maintain-
ing the function of the visual system. We have also found
that Cholecystokinin ismore abundant inprimary visual cortex,
compared to SC and LGN. It has been extensively studied in rat
cortex [59], and has been shown to be more abundant in young
animals and moderately down-regulated with age. Other
peptides such as CART, Pro-MCH or ACA-Peptide also exhibit
differential distribution across the studied visual system
areas, and more work is needed to describe how they sub
serve visual functions during development and adulthood.
We have observed two classical peptides from the VGF
family: AQEE-30 and neuroendocrine regulatory peptide-2.
They are linked to experience-induced plasticity in the visual
cortex and are down-regulated by an inhibition of retinal ac-
tivity during the critical phase of visual development [60,61].
Thus their abundance in adult animals tends to be very
low, but as our measurements show these peptides can still
be robustly observed in adult animals. Our peptide popula-
tion also includes a peptide from the vasoactive intestinal
polypeptide (VIP) family. VIP is present in many GABAergic
neurons, and is thought to be co-released with GABA during
interneuron activation. It has been shown that VIP can exert
substantial changes in activity of V1 neurons in the cat [62],
with effects depending on cortical layer. Thus, in addition
to being useful for labeling a specific kind of GABAergic in-
terneuron, VIP can also act as a neurotransmitter in V1 and
modify cortical computations. Further work is needed to clarify
the role of other peptides on visual processing.
Our study represents the first comprehensive characteri-
zation of peptides in the mammalian visual system. Com-
pared to immunochemical or autoradiography methods, our
MS-based analysis has demonstrated large coverage and
high sensitivity, as evidenced by the detection of a number
of peptides whose levels are down-regulated in the adult
animals that we studied. In addition, MS-based methods
can distinguish even closely related peptides, thus offering
superior selectivity and the possibility to ascribe physiologi-
cal functions to particular members of a peptide family with
high confidence.
5. Concluding remarks
The presented study deals with the investigation of expres-
sion levels of peptides in the tree shrew visual system areas
V1, LGN and SC. Using a synergy of DDA (data dependent
analysis) and targeted nanoLC-MS/MS approaches, we have
identified a total 53 peptides from 21 distinctive pro-hormone
families. We have discovered that a considerable fraction of
our peptides exhibits differential abundance across the
three visual system areas we investigated. The LGN was
found to be the least rich in peptides, whereas generally sim-
ilar peptide abundance was observed in SC and V1. Our study
uncovered differential expression levels of some key pep-
tides across targeted regions. Our results demonstrated that
in themammalian brain, NPY, SOM 28 and some of the opioid
peptides, were more abundant in V1, while SOM 28 AA1-12
and a peptide from the Acyl-CoA-binding protein family
were more abundant in the superior colliculus. We have
shown that our approach can be used for the differential
analysis of a population of peptides in the visual system,
which now opens the possibility to systematic investigations
of how behavioral or pharmacological manipulations impact
visual system peptide levels.
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